The Global Helicobacter Pylori Diagnostics Market, valued at approximately USD 601.2 million in 2022, is projected to grow at a robust CAGR of more than 6% during the forecast period from 2023 to 2030 ...
Fexuprazan is under clinical development by Daewoong and currently in Phase II for Helicobacter pylori Infections. According to GlobalData, Phase II drugs for Helicobacter pylori Infections have a 64% ...
ABSTRACT: Helicobacter pylori infection represents a widespread chronic condition with varying prevalence influenced by race, ethnicity, and geography. The severity of H. pylori-associated diseases is ...
The treatment is mainly focused on managing symptoms and preventing dehydration. Helicobacter pylori (H. pylori) is a type of bacteria associated with peptic ulcers. The infection is hard to treat and ...